Padagis is a pharmaceutical manufacturing company that specializes in the development, production, and distribution of generic and branded pharmaceutical products. The company was established in 2021 following the acquisition of Teva Pharmaceuticals’ U.S. generics business by Advent International. Headquartered in Parsippany, New Jersey, Padagis operates multiple manufacturing facilities across the United States and Israel. The company’s product portfolio includes topical medications, oral solid dosage forms, and complex drug products across various therapeutic categories. Padagis maintains a significant presence in dermatology, respiratory, and consumer healthcare markets. Their manufacturing capabilities encompass creams, ointments, lotions, solutions, suspensions, and oral solid dosage forms. Padagis holds a considerable market share in the generic pharmaceutical sector, with numerous Abbreviated New Drug Applications (ANDAs) approved by the U.S. Food and Drug Administration (FDA). The company employs over 1,000 people across its operations and maintains high standards of quality control and regulatory compliance in its manufacturing processes. The company’s business model focuses on vertical integration, from research and development through manufacturing and commercialization. Padagis continues to expand its product pipeline through internal development and strategic partnerships while maintaining its commitment to providing affordable pharmaceutical products to the healthcare market.